Legal Representation
Attorney
Tara Reedy Sliva
USPTO Deadlines
Next Renewal Deadline
796 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2017-09-12)
Due Date
September 12, 2027
Grace Period Ends
March 12, 2028
Application History
30 eventsDate | Code | Type | Description |
---|---|---|---|
Dec 12, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
Dec 12, 2023 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
Dec 12, 2023 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED |
Jun 14, 2023 | E815 | I | TEAS SECTION 8 & 15 RECEIVED |
Sep 12, 2022 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
Aug 18, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Aug 18, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Aug 18, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Sep 12, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Aug 10, 2017 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
Aug 9, 2017 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
Aug 9, 2017 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
Aug 5, 2017 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Jul 11, 2017 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Jul 11, 2017 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
Jul 11, 2017 | IUAF | S | USE AMENDMENT FILED |
Jan 17, 2017 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Nov 22, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION |
Nov 22, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Nov 2, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Oct 18, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
Oct 17, 2016 | ALIE | A | ASSIGNED TO LIE |
Sep 30, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Sep 27, 2016 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
Sep 27, 2016 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
Sep 27, 2016 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Sep 27, 2016 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
Sep 22, 2016 | DOCK | D | ASSIGNED TO EXAMINER |
Jun 20, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Jun 16, 2016 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Medicinal preparations for photosensitizing agents used as a dermatologic drug or prodrug for the treatment of skin cancer by phototherapy; Chemical reagents for medical and veterinarian use; Chemical reagents for cultures of microorganisms for medical use, namely, in culture media for the isolation and identification of the bacteria strain Escherichia coli O157:H7; Chemical preparations for medical purposes, namely, for Cholesterol testing to prevent possible consequences of Hypercholesterolemia such as atherosclerosis, coronary heart disease and other forms of cardiovascular diseases; Chemical preparations for medical purposes, namely, for novel enzyme responsive inhibitors that allow for modifications of the composition of microbial communities; Chemical preparations for medical purposes, namely, for immunology research; Organic chemical preparations for medical purposes, namely, immunomodulatory compounds with anti-inflammatory properties; Organic chemical preparations for medical laboratory analysis purposes, namely, for medical detection, identification and quantification of strains of pathogenic bacteria; Chemical preparations for medical laboratory analysis purposes, namely, for medical immunological and microbiological blood testing; Chemical preparations for medical laboratory analysis purposes, namely, used as a routine medical supplement to blood culture media in vitro to inhibit blood coagulation and to improve the detection limits for individual microorganisms; Chemical preparations for medical laboratory analysis purposes, namely, for medical detection of pathogenic bacteria, namely, various strains of Listeria, Clostridium, Bacillus and Staphylococcus; Chemical preparations for medical laboratory analysis purposes, namely, for the medical detection and quantification of bacteria strains of Escherichia coli; Medical preparations for the diagnosis of Staphylococus aureus, in particular for Methicillin-resistant Staphylococcus aureus (MRSA); Medical enzyme
First Use Anywhere:
Sep 29, 2006
First Use in Commerce:
Sep 29, 2006
Classification
International Classes
005